The stakes are enormous. According to GLOBOCAN 2022 estimates, nearly 20 million new cancer cases occurred worldwide in 2022, and China alone contributed approximately 4.82 million incident cases and 2.57 million deaths annually, representing close to a quarter of the global burden. Japan and South Korea face rising cancer incidence driven primarily by population ageing, while Australia reports among the highest age-standardised incidence rates in the world. Many of the region’s most common malignancies, including lung, breast, colorectal, prostate, and gastric cancers, are already amenable to biomarker-guided treatment, with actionable alterations such as EGFR mutations, ALK fusions, HER2 amplification, BRAF mutations, and mismatch repair deficiency now routinely detectable. Yet the authors emphasise that clinical impact depends on effective health-system implementation rather than technology alone.

The four countries were deliberately selected because they embody complementary implementation archetypes. Japan represents a nationally coordinated public model, in which cancer genomic medicine is embedded within universal health insurance through a three-tier network of Core, Designated, and Cooperative Hospitals operating under mandatory quality standards and compulsory molecular tumour board review. South Korea exemplifies a rapidly evolving but reimbursement-constrained system, where next-generation sequencing capacity has expanded quickly across tertiary hospitals and private laboratories, yet comprehensive genomic profiling often requires substantial out-of-pocket payment. China constitutes a large-scale, innovation- and market-driven ecosystem, propelled by public hospitals and a vast commercial diagnostics sector. Australia operates a research-integrated translational framework, in which broad genomic profiling remains largely confined to research programmes even as the country pioneers trial-linked molecular screening.

Each archetype produces characteristic bottlenecks along the patient pathway. In Japan, comprehensive genomic profiling is reimbursed mainly for patients who have exhausted standard therapies, restricting the clinical value of identifying actionable alterations earlier in the disease course. Indication-based reimbursement and limited off-label pathways create a persistent mismatch between genomic findings and treatment access, even though targeted drugs themselves are broadly available. In South Korea, a December 2023 policy revision raised patient co-payment rates from 50 percent to 80 percent for most cancers, further constraining access despite rapid regulatory approval of targeted agents. China has achieved the widest availability of genomic testing, particularly in urban centres, but most tests are self-funded and provincial variation in insurance coverage produces profound urban-rural inequities. Australia captures the paradox in a single phrase used by the authors: right test, wrong access, describing a system where the Pharmaceutical Benefits Scheme provides broad drug coverage but indication-based rules limit biomarker-driven off-label use.

Molecular tumour boards, the multidisciplinary forums that translate genomic data into treatment decisions, emerge as a second critical determinant. Japan operates one of the most standardised systems globally, with boards convened at all Core and Designated Hospitals and linked directly to reimbursement. South Korea has widely adopted institutional boards, though formats, documentation, and authority vary between hospitals, and boards typically function in an advisory capacity. China exhibits a spectrum of models ranging from academic boards to commercially facilitated services. Australia concentrates board activity in metropolitan research-intensive cancer centres. The South Korean KOSMOS-I pilot study offers a striking demonstration of what coordinated governance can achieve: a nationwide virtual central molecular tumour board spanning 29 sites delivered molecularly guided therapy to 51 percent of enrolled patients between 2021 and 2022, and the ongoing KOSMOS-II trial has expanded the platform to 31 centres with a clinico-genomic database.

Research-integrated ecosystems prove to be the region’s most powerful accelerators. Japan’s SCRUM-Japan programme has enrolled more than 40,000 patients in nationwide genomic screening, and its MONSTAR-SCREEN initiative has conducted 17 investigator-initiated trials across tumour types using multi-omics profiling. Critically, the SCRUM-MONSTAR ecosystem has demonstrated measurable survival benefit: patients receiving genomically matched therapies achieved a median overall survival of 19.1 months compared with 15.3 months for those receiving non-matched therapy, a hazard ratio of 0.767. The accompanying SCRUM-Japan Registry accumulates regulatory-grade real-world data that have even supported drug approvals as external control data. Meanwhile, the BELIEVE/NCCH1901 basket trial, run under Japan’s Patient-Proposed Healthcare Services framework, has enrolled over 290 patients across 18 cohorts, providing genomically guided access to selected off-label agents. South Korea’s K-MASTER programme sequenced approximately 8,000 patients across 55 institutions between 2017 and 2021, while Australia contributes initiatives such as PrOSPeCT, ASPiRATION, and the SUPER-NEXT programme applying whole-genome and transcriptome sequencing to cancers of unknown primary.

Data governance is identified as an emerging strategic inflection point. Japan’s C-CAT platform exemplifies centralised genomic-clinical data collection, complemented by the 2023 Act on the Promotion of Genome Medicine, though interoperability with other national health datasets remains limited. South Korea launched a national cancer clinical and genomic database in 2025 covering roughly 67 percent of cases nationwide, building on the K-CURE project. China operates under the strict constraints of the Personal Information Protection Law and Data Security Law, which are simultaneously driving adoption of federated analytic models that permit collaboration without raw data transfer. Australia has established Genomics Australia, a new national agency finalising the National Health Genomics Policy Framework and Implementation Plan 2026-2030. The authors argue that federated data infrastructures, harmonised standards, and secure cross-border analytic frameworks are essential for building learning health systems while respecting national privacy and sovereignty requirements.

Equity concerns thread through every domain of the analysis. Workforce shortages in molecular pathology, clinical genetics, genetic counselling, and bioinformatics afflict all four countries, reflecting testing expansion that has outpaced training capacity. Geographic disparities persist, from age-related and institutional variation in Japan to the gaps experienced by Aboriginal and Torres Strait Islander peoples and remote communities in Australia. Rare cancers, paediatric malignancies, and patients with uncommon genomic alterations are disproportionately vulnerable because limited case volumes restrict companion diagnostics, specialist expertise, and matched trials. The review also documents divergent approaches to genetic discrimination: South Korea’s Bioethics and Safety Act explicitly prohibits discrimination based on genetic information, Australia enacted legislation in 2026 banning the use of genetic information in life insurance, while Japan and China lack legally binding protections. The authors insist that equity must be treated as a systems-level property shaped by governance and reimbursement policy, not merely a patient-level problem.

Looking forward, the review proposes seven priority actions, from broadening eligibility for comprehensive genomic profiling beyond late-line settings and harmonising molecular tumour board governance, to adaptive health technology assessment, workforce investment, federated data infrastructure, equity-targeted interventions, and structured regional collaboration. Emerging technologies may shift the field upstream: maturing multi-omics platforms, circulating tumour DNA-based minimal residual disease assays, and evidence supporting first-line genomic profiling in untreated metastatic cancers all argue for earlier testing. Artificial intelligence is expected to relieve workforce pressure, with a Japanese national evaluation showing higher concordance between AI-assisted treatment recommendations and expert consensus than conventional molecular tumour board processes. The central lesson, the authors conclude, is that success in precision oncology should be measured not by sequencing capacity but by the ability to connect molecular findings to matched therapies and improved outcomes, a goal that coordinated regional collaboration across the Asia-Pacific could now make achievable at scale.

Subject of Research: A comparative assessment of cancer genomics and precision oncology implementation, access, and policy across Japan, South Korea, China, and Australia.

Article Title: Landscape of cancer genomics and precision oncology in Japan, South Korea, China, and Australia

Article References: Bando, H., Okayama, H., Chang, Y. J., Yu, J., Grimmond, S. M., Kong, S.-Y., Hu, X., Zeps, N., Han, J.-Y., Kim, J.-I., Seguchi, K., Amisaki, M., Sakamoto, Y., Fujisawa, T., Yamashita, R., Kato, K., Kono, K., Johns, A., & Yoshino, T. (2026). Landscape of cancer genomics and precision oncology in Japan, South Korea, China, and Australia. The Lancet Regional Health – Western Pacific, Article 101981. https://doi.org/10.1016/j.lanwpc.2026.101981

Image Credits: AI Generated

DOI: 10.1016/j.lanwpc.2026.101981

Keywords: precision oncology, cancer genomics, comprehensive genomic profiling, molecular tumour boards, SCRUM-MONSTAR, health policy, reimbursement, data governance, health equity, Asia-Pacific, targeted therapy, clinical trials

Employing a comprehensive NGS panel that targets 72 cancer-related genes, researchers meticulously analyzed lung resection specimens from 41 LSCC patients. The meticulous genomic profiling revealed a breadth of mutations that emphasized the genetic complexity inherent in this cancer type. Remarkably, mutations were detected in 23 distinct genes, with a total of 94 mutational events recorded. The findings underscore the critical role of high-throughput sequencing in expanding our understanding of previously elusive genetic drivers in LSCC.

Among the array of genetic alterations identified, mutations in the tumor suppressor gene TP53 emerged as the most prevalent, appearing in approximately 31% of detected mutations. This is consistent with previous knowledge that TP53 plays a pivotal role in cell cycle regulation and genome integrity. However, this study moved beyond TP53 by identifying significant mutation frequencies in several other key genes, including NF1, PTEN, and PIK3CA, which are traditionally less characterized in the context of LSCC.

Of particular interest was the identification of NF1 mutations in approximately 20% of cases. The NF1 gene, known for its regulatory role in the RAS signaling pathway, has often been overshadowed by more prominent oncogenic drivers in lung cancer studies. This discovery reveals a potential novel avenue for therapeutic targeting and prognostic assessment in LSCC, offering hope for more precise interventions tailored to the tumor’s molecular landscape.

The tumor suppressor gene PTEN, mutated in nearly 12% of cases, demonstrated intriguing associations with histopathological features. The study revealed a statistically significant relationship between PTEN mutations and mild inflammatory reactions within the tumor microenvironment. This connection may provide insight into the intricate interplay between genetic alterations and the immune milieu, potentially guiding future strategies for immunotherapy combinations in LSCC management.

Furthermore, PIK3CA mutations, though less frequent at just over 5%, were linked with younger patient age and more aggressive clinicopathological parameters, including advanced tumor stage and increased inflammatory infiltration. This suggests that PIK3CA alterations may not only serve as biomarkers for disease stratification but could also represent actionable targets within the PI3K/AKT signaling axis, a pathway frequently exploited in cancer therapeutics.

The spatial distribution of these mutations added another layer of nuance to the findings. For instance, PTEN mutations showed a trend towards central tumor localization, while NF1 mutations correlated with visceral pleural involvement, indicating possible roles in tumor invasion and metastatic potential. These associations between mutational status and anatomical features could refine surgical and therapeutic decision-making processes in clinical practice.

While several p-values reported border on traditional significance thresholds, the emerging patterns warrant further validation in larger cohorts. Nonetheless, these trends contribute vital clues into the biological behavior of LSCC and stress the necessity of integrating genomic data with histopathological and clinical parameters to form a more holistic understanding of tumor biology.

The study’s implications extend beyond the immediate findings. In an era where personalized medicine transforms oncology, LSCC has trailed behind adenocarcinoma regarding targeted therapies due to its less defined mutation spectrum. This research bridges that gap by not only mapping previously unreported mutations but also emphasizing the heterogeneity within LSCC. Such molecular insights pave the way for the development of tailored therapeutic regimens that move away from one-size-fits-all treatments.

Moreover, the findings caution against oversimplified approaches that cluster multiple genetic alterations indiscriminately. The researchers highlight that grouping alterations risks overlooking true driver mutations crucial for therapy responsiveness. This insight calls for refined bioinformatics tools and clinical algorithms to discern meaningful mutation patterns for precision oncology.

In the context of clinical application, the study advocates for routine mutational profiling in all LSCC patients. Recognizing and characterizing driver mutations could revolutionize therapeutic strategies, guiding oncologists toward effective targeted agents or combination therapies that were previously underutilized or unexplored in LSCC care.

Finally, this study underscores the vital link between molecular genetics and histopathology in shaping future lung cancer treatment paradigms. By identifying associations between specific mutations and histological features such as inflammatory reaction and tumor localization, the research illuminates potential predictive markers that may optimize patient stratification and follow-up regimens.

In conclusion, this comprehensive genomic investigation into LSCC driver mutations heralds a promising advance in the understanding and management of this aggressive cancer. The identification of NF1, PTEN, and PIK3CA mutations as significant contributors to LSCC pathogenesis opens avenues for novel diagnostic and therapeutic approaches. As genomic technologies continue to evolve, integrating detailed mutation landscapes with clinical and pathological data will be paramount to realizing the full potential of personalized medicine in lung cancer.

Subject of Research: Mutation Profiles in Lung Squamous Cell Carcinoma

Article Title: Relationship Between Mutation Profile Detected by Next-generation Sequencing and Histopathological Parameters in Lung Squamous Cell Carcinoma

News Publication Date: 15-Apr-2025

Web References:
https://www.xiahepublishing.com/journal/jctp
http://dx.doi.org/10.14218/JCTP.2025.00001

Keywords: Lung Squamous Cell Carcinoma, Lung Cancer, Next Generation Sequencing, Tumor Mutation Profiling, TP53, NF1, PTEN, PIK3CA, Targeted Therapy, Histopathology, Molecular Pathology